Henlius Biotech

BRIEF: Fosun Pharma raises stake in Henlius

Fosun Pharma (2196.HK) announced on Monday that its wholly owned unit, Fosun Pharma Industrial, acquired 21.03 million unlisted shares of its Henlius (2696.HK) subsidiary for HK$517 million ($66.6 million), or…
2196.HK 2696.HK
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
9926.HK
The drugs maker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings.

Debt pressures cast cloud over Fosun Pharma results

The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
2196.HK 600196.SHG

Recent Articles

RELATED ARTICLES

  1. Henlius Bio
    After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  2. Fosun moves on from debt crisis with renewed focus on tourism, healthcare
    0656.HK
  3. Fosun Tourism travels back to home base with delisting plan
    1992.HK 0656.HK
  4. BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
    2196.HK 600196.SHG
  5. Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  6. Battered Lanvin hopes for better 2025 as executive revolving door keeps turning
    LANV.US
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva